Literature DB >> 10872734

Improvements in the selective perception and training of rats using an original analog of the C-terminal fragment of vasopressin.

N S Ponomareva1, O G Voskresenskaya, A A Kamenskii, V P Golubovich, I P Ashmarin.   

Abstract

This report presents studies on the effects of intranasal administration of five doses (0.001, 0.01, 0.1, 1, and 10 microg/kg) of a new analog of arginine-vasopressin fragment AVP(6-9), i.e., D-MPRG, on the learning ability of rats with positive and negative reinforcement. All doses of the peptide improved learning. The most effective dose was 0.01 microg/kg, at which the peptide accelerated the acquisition of a conditioned active avoidance reflex both when given 1 h before and when given immediately after training sessions. The peptide had greater effects when animals were trained with negative reinforcement. Analysis of the results suggests that the action of D-MPRG is mainly on perception processes, i.e., extraction of the conditioned stimulus from the environmental surroundings and evaluation and enhancement of its biological significance. In addition, this peptide prevented extinction of the acquired habit and improved the processes of consolidation, though this effect was weaker than its effect on perception.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10872734     DOI: 10.1007/bf02463162

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  7 in total

1.  Cysteinyl methyl ester of AVP(4-8), a potent agonist on the maintenance of passive avoidance in rats.

Authors:  C Lin; R Y Liu; Y C Du
Journal:  Peptides       Date:  1990 Jul-Aug       Impact factor: 3.750

Review 2.  Vasopressin and vasopressin analogues for treatment of memory disorders in clinical practice.

Authors:  J J Legros; M Timsit-Berthier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

3.  The effect of vasopressin analog: [d(CH2)(1)5,Tyr(Me)2,delta 3Pro7]AVP on learning and memory processes in rats with experimental amnesia.

Authors:  H Car; M Borawska; K Wiśniewski
Journal:  Pol J Pharmacol       Date:  1993 Jan-Feb

4.  Nasal delivery of polypeptides I: nasal absorption of enkephalins in rats.

Authors:  K S Su; K M Campanale; L G Mendelsohn; G A Kerchner; C L Gries
Journal:  J Pharm Sci       Date:  1985-04       Impact factor: 3.534

5.  Differential effects of ACTH4-10, DG-AVP, and DG-OXT on heart rate and passive avoidance behavior in rats.

Authors:  R Wan; M Diamant; W de Jong; D de Wied
Journal:  Physiol Behav       Date:  1992-03

6.  Subcutaneous administration of behaviorally effective doses of arginine vasopressin change brain AVP content only in median eminence.

Authors:  S N Deyo; W J Shoemaker; A Ettenberg; F E Bloom; G F Koob
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

7.  A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide.

Authors:  J P Burbach; G L Kovács; D de Wied; J W van Nispen; H M Greven
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.